CGON
CG Oncology, Inc.Company Information
- Company Name
- CG Oncology, Inc.
- CIK
- CIK0001991792
- Category
- Large accelerated filer
- Ticker: Exchange
- CGON: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- CGON
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-25
- Last sale
- 2026-09-15
- Shares purchased (TTM)
- 371,085
- Shares sold (TTM)
- 99,070
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 82,682,511
- Shares outstanding
- 88,200,023
- Ownership
- 93.74%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -0.68%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 20 | 34 | 32 | 45 | 15 | 41 | 257 | 43 | 25 | 77 | ||||||
| Marketable Securities Current | 1,009 | 1,043 | 710 | 635 | 646 | 647 | 485 | 497 | 528 | 489 | ||||||
| Inventory Net | 1 | 1 | 2 | 2 | - | - | 0 | - | - | - | ||||||
| Receivables Net Current | 0 | 1 | 1 | 1 | - | - | 0 | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 20 | 23 | 15 | 14 | 11 | 12 | 12 | 11 | 11 | 12 | ||||||
| Assets Current | 1,050 | 1,102 | 759 | 696 | 673 | 701 | 754 | 552 | 564 | 579 | ||||||
| Property Plant And Equipment Net | 15 | 15 | 16 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 6 | 5 | 4 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Finite Lived Intangible Assets Net | 1 | 1 | 1 | 2 | - | - | 0 | - | - | - | ||||||
| Deferred Costs | - | - | - | - | - | - | 0 | - | - | - | ||||||
| Goodwill | 10 | 10 | 10 | 13 | 10 | - | 0 | - | - | - | ||||||
| Accounts And Other Receivables Net Current | - | - | - | - | 1 | 0 | 1 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 5 | 3 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Assets | 1,086 | 1,135 | 792 | 730 | 701 | 728 | 755 | 552 | 564 | 579 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||
| Notes And Loans Receivable Net Noncurrent | - | - | - | - | 27 | 25 | - | - | - | - | ||||||
Liabilities Current | ||||||||||||||||
| Accounts Payable Current | 13 | 8 | 6 | 9 | 7 | 7 | 7 | 4 | 4 | 5 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accrued Liabilities And Other Liabilities | 34 | 26 | 24 | 20 | 23 | 16 | 15 | 11 | 7 | 5 | ||||||
| Liabilities Current | 47 | 35 | 31 | 31 | 30 | 23 | 21 | 16 | 12 | 10 | ||||||
| Long Term Debt Noncurrent | 3 | 3 | 3 | 3 | - | - | 0 | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 5 | 4 | 3 | 3 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities | 0 | 0 | 0 | 2 | - | - | 0 | - | - | - | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 2 | 4 | - | - | 0 | - | - | - | ||||||
| Liabilities | 57 | 43 | 39 | 42 | 31 | 23 | 21 | 16 | 12 | 10 | ||||||
Stockholders Equity | ||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,547 | 1,531 | 1,132 | 1,025 | 964 | 957 | 951 | 723 | 718 | 716 | ||||||
| Retained Earnings Accumulated Deficit | -518 | -439 | -379 | -338 | -294 | -252 | -218 | -186 | -166 | -147 | ||||||
| Series A1 Redeemable Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Stockholders Equity | 1,029 | 1,092 | 753 | 688 | 670 | 705 | 733 | 537 | 552 | 569 | ||||||
| Series B Redeemable Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Liabilities And Stockholders Equity | 1,086 | 1,135 | 792 | 730 | 701 | 728 | 755 | 552 | 564 | 579 | ||||||
| Series C Redeemable Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Series D Redeemable Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Series E Redeemable Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Series F Redeemable Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 700 | 700 | 700 | 700 | 700 | 700 | 700 | 700 | 700 | 700 | ||||||
| Common Stock Shares Issued | 88 | 88 | 81 | 78 | 76 | 76 | 76 | 68 | 67 | 67 | ||||||
| Shares Outstanding | 88 | 88 | 81 | 78 | 76 | 76 | 76 | 68 | 67 | 67 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCG Oncology, Inc. (CGON) — SEC Financial Statements & Analysis
CG Oncology, Inc. (CGON) is a biological products, (no diagnostic substances) company, incorporated in DE. CG Oncology, Inc. trades on Nasdaq as: CGON. CG Oncology, Inc. (CGON)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, CG Oncology, Inc. carries a market cap of $6.27B, a P/E ratio of -27.93x, a P/B ratio of 6.09x, a P/S ratio of 1006.20x, an enterprise value of $6.25B, and an EV/EBITDA multiple of -25.03x. On profitability, it posts a gross margin of -85.20%, an operating margin of -4056.18%, a net margin of -3602.68%, a Return on Equity (ROE) of -26.41%, a Return on Assets (ROA) of -25.11%, and a Return on Invested Capital (ROIC) of -30.28%. Per share, it reports EPS of $-2.54, diluted EPS of $-2.54, free cash flow per share of $-2.03, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 1030.31% year-over-year, net income growth of 75.18% year-over-year, and EPS growth of 51.40% year-over-year. On the balance sheet, it maintains a current ratio of 22.22x, a quick ratio of 21.78x, working capital of $1.00B, a debt-to-equity ratio of 0.05x, a debt ratio of 0.05, free cash flow of $-179.34M (TTM), and net debt of $-16.64M. Figures sourced from SEC EDGAR.
- Market Cap
- $6.27B
- P/E TTM
- -27.93x
- EPS TTM
- $-2.54
- P/B TTM
- 6.09x
- ROE TTM
- -26.41%
- ROA TTM
- -25.11%
- Debt To Equity
- 0.05x
- Free Cash Flow TTM
- $-179.34M
- Net Revenue TTM Growth 1Y
- 1030.31%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is CG Oncology, Inc. in?
CG Oncology, Inc. (CGON) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does CGON trade on?
CG Oncology, Inc. (CGON) trades on the Nasdaq.
Where is CG Oncology, Inc. incorporated?
CG Oncology, Inc. is incorporated in DE.
When was CG Oncology, Inc. (CGON)'s most recent SEC filing?
CG Oncology, Inc. (CGON)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is CGON's market cap?
CG Oncology, Inc. (CGON) has a market capitalization of $6.27B as of 2026-06-30.
What is CGON's EPS (earnings per share)?
CG Oncology, Inc. (CGON)'s trailing twelve month EPS is $-2.54 as of 2026-06-30.
What is CGON's ROE (return on equity)?
CG Oncology, Inc. (CGON)'s trailing twelve month Return on Equity (ROE) is -26.41% as of 2026-06-30.
What is CGON's ROA (return on assets)?
CG Oncology, Inc. (CGON)'s trailing twelve month Return on Assets (ROA) is -25.11% as of 2026-06-30.
What is CGON's ROIC (return on invested capital)?
CG Oncology, Inc. (CGON)'s trailing twelve month Return on Invested Capital (ROIC) is -30.28% as of 2026-06-30.
What is CGON's EV/EBITDA?
CG Oncology, Inc. (CGON)'s trailing twelve month EV/EBITDA is -25.03x as of 2026-06-30.